Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive July 1, 2009	French Revolution Chris Viehbacher's first fast and furious six months at the top of Sanofi-Aventis have heads spinning... and rolling.
The Motley Fool February 12, 2009 Brian Orelli	Patent Cliff? Bring It On Sanofi-aventis isn't interested in doing a large deal.
The Motley Fool May 5, 2009 Robert Steyer	Sanofi-Aventis' To-Do List The French drugmaker seeks acquisitions to reinforce and expand its business geographically and scientifically.
The Motley Fool February 9, 2009 Robert Steyer	Just Say No to Drug Company Mergers There are some reasons to make a big-pharma deal. But there are as many, if not more, reasons to let these companies pursue smaller deals and collaborations rather than become just another part of a hyphenated corporate name.
BusinessWeek December 9, 2009 Kelley & Torsoli	Major Surgery at Sanofi CEO Chris Viehbacher has been on a buying spree and a charm offensive, both of which are reversing the drugmaker's losing streak.
The Motley Fool August 31, 2005 Stephen D. Simpson	Sanofi-Aventis: A Mix of News The company gave investors a lot of information for the second quarter, with not all of it positive.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool September 11, 2008 Brian Lawler	Will a Change Cure Sanofi? The drugmaker charts a different course for its future.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool March 9, 2005 Brian Gorman	Sanofi's Answer to Obesity Sanofi-Aventis will ask for FDA approval of an exciting new drug that may work for a variety of addictions.
The Motley Fool November 17, 2009 Dave Mock	A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst.
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
The Motley Fool January 29, 2007 Brian Lawler	The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note.
BusinessWeek February 9, 2004 Kerry Cappell	This Bid Looks Like Bad Medicine Sanofi's lowball offer for giant drugmaker Aventis is unwise for both companies
BusinessWeek December 27, 2004 Kerry Capell	The End Of Obesity As We Know It Sanofi-Aventis' Acomplia takes aim at two of the great maladies of the century. But approval isn't a slam dunk.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool May 5, 2006 Stephen D. Simpson	Sanofi-Aventis Waits It Out This is the hurry up-and-wait part of the French pharma's story, with product approvals on the way soon, investors hope.
The Motley Fool February 11, 2010 Brian Orelli	A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.
The Motley Fool July 24, 2009 Brian Orelli	Bristol-Myers: Eat or Be Eaten Bristol-Myers Squibb, the oft-rumored acquisition target of partner sanofi-aventis, is doing a little acquiring of its own, which might settle down the rumor mill.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool September 24, 2008 Brian Lawler	Sanofi Gets the Golden Ring Sanofi-Aventis raises its bid and acquires Czech generic drugmaker Zentiva.
The Motley Fool September 25, 2008 Brian Lawler	Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors.
The Motley Fool February 20, 2007 Brian Lawler	Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead.
Chemistry World February 17, 2011 Sarah Houlton	Sanofi to buy Genzyme in $20 billion deal Sanofi-Aventis has won its long-running battle for Genzyme, and is to acquire the US-based biotech for $74 ( 46) per share - about $20 billion in total - plus extra payments of up to $14 per share.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
The Motley Fool October 22, 2010 Anand Chokkavelu	7 Big Pharma Stocks Near 52-Week Lows Trolling the bottom for upside potential.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool May 13, 2005 Stephen D. Simpson	Waiting for Sanofi's Next Act Sanofi-Aventis' first-quarter numbers were good. Will they soon be better? Though the stock is not the greatest idea for highly income-oriented investors, the growth-at-a-reasonable-price crowd might want to investigate further.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool November 12, 2009 Kris Eddy	Drug Companies Should Think Smaller Sanofi-aventis looks to break R&D into smaller chunks; their collaboration with Regeneron Pharmaceuticals is a good example of the new strategy.
The Motley Fool December 23, 2009 Brian Orelli	2009 Cheers and Jeers for Pharma Unfortunately, it was more of the latter.
BusinessWeek December 27, 2004 Carol Matlack	Growing Pains At Sanofi The pipeline looks good at the world's No. 3 drugmaker -- but investors are waiting for cost cuts.
The Motley Fool December 31, 2007 Brian Lawler	Big Pharma 2008 Forecast Roundup Investors, take a look at what 2008 has in store for big pharma.
The Motley Fool January 26, 2009 Brian Orelli	Have Drugs, Will Travel After buying Bristol-Myers Squibb's businesses in Egypt and Pakistan, GlaxoSmithKline is now off to Africa.
The Motley Fool March 30, 2009 Brian Orelli	Hopes Fall Short for Arena Pharmaceuticals Arena Pharmaceuticals' obesity drug lorcaserin doesn't look like it's doing enough to be a marketing success -- and the results might not even be enough to get it past the Food and Drug Administration.
The Motley Fool June 15, 2009 Brian Orelli	Strange Bedfellows GlaxoSmithKline is teaming up with none other than its arch-nemesis, generic-drug maker Dr. Reddy's Laboratories, licensing more than 100 of their brands to sell in emerging markets.
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.
The Motley Fool January 26, 2005 Stephen D. Simpson	Sanofi's Balancing Act A broad portfolio of drugs helps the French pharmaceutical stay ahead of its peers. It's a good option for investors who want a strong growth stock in the pharmaceutical space but don't want to take on the risks of turnarounds or litigation.
The Motley Fool May 21, 2010 Brian Orelli	Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
The Motley Fool March 30, 2011 Sean Williams	China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps.
The Motley Fool October 30, 2007 Brian Orelli	Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note.
Chemistry World October 5, 2010 Andrew Turley	Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board.
The Motley Fool July 31, 2009 Brian Orelli	Can Emerging Markets Save Pharma? Probably not until after they emerge.
The Motley Fool January 31, 2011 Brian Orelli	Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities.
The Motley Fool June 21, 2007 Billy Fisher	A Bull-Run at Bristol The strength of its oncology pipeline sets Bristol-Myers apart from its peers. Regardless of whether the company is ultimately taken over, shareholders are definitely in a better position than they have been in recent years.
The Motley Fool June 21, 2010 Julie Clarenbach	Which Drugmaker Is a Buy? A look at some numbers to weigh one against another.
The Motley Fool March 19, 2009 Brian Orelli	One Down, One to Go Sanofi-aventis slides past an FDA panel and hopes for more good news today
The Motley Fool March 27, 2009 Brian Orelli	Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with.